Form 4: Centessa Pharmaceuticals CEO Executes Pre-Planned Option Exercise and Share Sale
Insider Transaction Report
Centessa Pharmaceuticals plc CEO Saurabh Saha exercised stock options and sold an equivalent number of shares on July 21, 2025, under a pre-established Rule 10b5-1 trading plan.
Summary
- Saurabh Saha, Chief Executive Officer and Director of Centessa Pharmaceuticals plc, engaged in a pre-planned transaction on July 21, 2025.
- Exercised 55,000 share options at an exercise price of $3.85 per share.
- Simultaneously sold 55,000 Ordinary Shares at a weighted average price of $15.92 per share, with individual sales ranging from $15.80 to $16.05.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
- Following these transactions, direct beneficial ownership of Ordinary Shares decreased to 221,017, while 38,000 shares are held indirectly by a trust.
- The number of beneficially owned share options decreased to 150,000.
Sentiment
Score: 7
Explanation: The CEO exercised options and sold shares at a significant profit, which is a positive for the individual. The transaction was pre-planned under a Rule 10b5-1 plan, suggesting it's a routine liquidity event rather than a signal of negative company performance.
Positives
- The CEO realized a significant profit by selling shares at a weighted average price of $15.92 after exercising options at $3.85.
- The transaction was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.
Negatives
- The CEO sold 55,000 shares, reducing direct beneficial ownership.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- 38,000 Ordinary Shares are held indirectly by a trust for which the Reporting Person and his spouse serve as trustees.
Stakeholder Impact
- Shareholders may view the CEO's sale of shares as a routine liquidity event, especially given the Rule 10b5-1 plan, rather than a negative signal about the company's future. The transaction demonstrates the value of executive compensation through stock options.
Key Dates
| Date | Description |
|---|---|
| 2023-03-01 | First installment vesting date for the share options. |
| 2024-05-16 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-07-21 | Date of the option exercise and share sale transactions. |
| 2033-02-01 | Expiration date of the share options. |
Recommendation
holdKeywords
Centessa Pharmaceuticals, CNTA, Saurabh Saha, SEC Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, CEO, Director, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.